Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Infection susceptibility increased? 31 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 31 reports of Infection susceptibility increased have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 0.1% of all adverse event reports for OMALIZUMAB.

31
Reports of Infection susceptibility increased with OMALIZUMAB
0.1%
of all OMALIZUMAB reports
0
Deaths
16
Hospitalizations

How Dangerous Is Infection susceptibility increased From OMALIZUMAB?

Of the 31 reports, 16 (51.6%) required hospitalization, and 11 (35.5%) were considered life-threatening.

Is Infection susceptibility increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 31 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Infection susceptibility increased?

ADALIMUMAB (179) ETANERCEPT (160) OCRELIZUMAB (118) METHOTREXATE (95) PREDNISONE (67) DIMETHYL (64) MYCOPHENOLATE MOFETIL (64) PREDNISOLONE (62) SECUKINUMAB (59) TOFACITINIB (57)

Which OMALIZUMAB Alternatives Have Lower Infection susceptibility increased Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Infection susceptibility increased Reports All Drugs Causing Infection susceptibility increased OMALIZUMAB Demographics